SCHEMBL7180933

SCHEMBL7180933

Cc1cc(C)c(C)c(C(=O)c2ccccc2[P](=O)C(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c1C

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 2/20 0.39
KCNK3 O14649 2/20 0.35
KCNK9 Q9NPC2 2/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
ALDH1A1 P00352 1/20 0.34
ALOX12 P18054 1/20 0.34
RORC P51449 4/20 0.34
CTSS P25774 1/20 0.33
RECQL P46063 1/20 0.33
PTGS1 P23219 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
F2R P25116 1/20 0.33
DHODH Q02127 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7187550 0.93 TAS2R14 (0.38) TAS2R14KCNK3KCNK9LMNAGAA
SCHEMBL7730584 0.92 TAS2R14 (0.37) TAS2R14KCNK3KCNK9LMNAGAA
SCHEMBL7181426 0.91 TAS2R14 (0.41) TAS2R14KCNK3KCNK9LMNAGAA
SCHEMBL7180491 0.90 TAS2R14 (0.39) TAS2R14KCNK3KCNK9LMNAGAA
SCHEMBL7175306 0.89 TAS2R14 (0.39) TAS2R14KCNK3KCNK9LMNAGAA
SCHEMBL7186793 0.88 KCNK3 (0.37) TAS2R14KCNK3KCNK9LMNAGAA
SCHEMBL7180621 0.88 TAS2R14 (0.38) TAS2R14KCNK3KCNK9LMNAGAA
SCHEMBL7188665 0.87 MEN1 (0.38) TAS2R14KCNK3KCNK9LMNAGAA
SCHEMBL7178036 0.86 KMT2A (0.37) KCNK3KCNK9LMNAGAAALDH1A1
SCHEMBL7180482 0.83 ALDH1A1 (0.33) LMNAGAAALDH1A1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TAS2R14 2184/4885KCNK3 351/4885KCNK9 352/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 TAS2R14 2410/4885KCNK3 388/4885KCNK9 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.